Practice Insights
2025/09/07
SUN PHARMA LAUNCHES HAIR LOSS DRUG IN THE UNITED STATES AFTER PATENT DISPUTE SETTLEMENT WITH INCYTE
On July 14, 2025, Sun Pharmaceutical Industries Ltd. (“Sun Pharma”), a generic drug manufacturer based in Bombay, India, announced the settlement of a patent infringement lawsuit with US-based biopharmaceutical corporation Incyte Corporation (“Incyte”) related to its hair loss drug LEQSELVI and the subsequent launch of that drug in the United States for the treatment of adults with severe alopecia areata.
2025/06/25
On May 28, 2025, Novartis announced that its new generation of anti vascular endothelial growth factor (anti-VEGF) monoclonal antibody, Brolucizumab (trade name: Beiyoushi®), was approved by the National Medical Products Administration of China, and its indication was diabetes macular edema (DME). The application for marketing license of Busizumab for the treatment of neovascular (wet) age-related macular degeneration (wAMD) and proliferative diabetes retinopathy (PDR) indications has been submitted to the National Medical Products Administration in October 2024 and December 2024 respectively.
2025/06/25
On June 11, 2025, several animation and film studios — including Disney, Marvel, Lucasfilm, 20th Century Studios, Universal Pictures, and DreamWorks Animation — jointly filed a lawsuit accusing AI image generator company Midjourney of infringing on their character copyrights. The characters include Darth Vader from Star Wars, Elsa from Frozen, and the Minions from Despicable Me.
2025/06/25
On April 24, 2025, Halozyme, Inc. (“Halozyme”), a biotechnology company notably developing innovative drug delivery technologies, filed a patent infringement lawsuit against pharmaceutical giant Merck Sharp & Dohme Corp. (“Merck”) in the U.S. District Court for the District of New Jersey.
2025/06/25
Merck (MSD) recently announced that its investigational oral PCSK9 inhibitor, Enlicitide Decanoate (MK-0616), has achieved positive results in two pivotal Phase III clinical trials, marking a significant step forward in the treatment of hyperlipidemia. This progress positions Enlicitide Decanoate to potentially become the first oral PCSK9 inhibitor approved by the U.S. FDA, offering a more convenient therapeutic option for the prevention and management of cardiovascular disease.
